January 24, 2021 -- Radius Health, Inc. recently unveiled a detailed fact sheet about its drug RAD011, a synthetic cannabidiol oral solution, which is being studied as a possible treatment for hyperphagia and related behaviors in Prader-Willi syndrome. The fact sheet also gives a description of Radius Health's upcoming SCOUT-015 clinical trial. According to Radius Health, the SCOUT-015 clinical study will be a "global randomized, double-blind, placebo-controlled study in PWS with around 200 patients, and a seamless phase 2/3 design to allow for evaluation of multiple dose groups and Intent-To-Treat efficacy analysis with both Phase 2 and Phase 3 cohorts."
Currently, Radius Health is in the process of recruiting sites for the SCOUT-015 clinical trial and is not yet recruiting patients. PWSA | USA will continue to provide updates on the status of the SCOUT-015 study and the progress of RAD011.
You can download the RAD011 Fact Sheet by clicking here.
More information about Radius and RAD011 can be found at clinicaltrials.gov.